(2S,4R)-N-((1R)-2-chloro-1-((3R,4R,5S,6R)-3,4,5-trihydroxy-6-(methylthio)-tetrahydro-2H-pyran-2-yl)propyl)-1-methyl-4-propylpyrrolidine-2-carboxamide

Absorption
Oral
Rapidly absorbed. C max is 2.5 mcg/mL. T max is 45 min. Bioavailability is 90%.

IM
T max is 3 h (adults) and 1 h (children).

IV
C max is 7 to 14 mcg/mL.

Vaginal
About 5% is absorbed (cream); 30% (suppositories).

Distribution
Widely distributed (including bones); no significant levels attained in CSF. Excreted in breast milk.

Metabolism
Rapidly converted to active clindamycin.

Elimination
The t ½ is 2.4 to 3.2 h. About 10% of bioactivity is excreted in the urine and 3.6% in the feces; the remainder is excreted as inactive metabolites.

Special Populations
Renal Function Impairment
The t ½ is increased slightly. Dosage adjustment is not usually needed.

Hepatic Function Impairment
The t ½ is increased slightly. Dosage adjustment is not usually needed.

Elderly
The t ½ is increased slightly. Dosage adjustment is not usually needed.

Erythromycin
May cause antagonism.

Kaolin-pectin antidiarrheals
May delay absorption of clindamycin.

Nondepolarizing neuromuscular blockers
May enhance actions of neuromuscular blocking agents.